Professor of Urology, University Tex Houston
Urology
Dr. Colin P. Dinney, MD
|
|
Give Review
Colin Dinney practices Urology. He over the years received 2 awards: "Top Doctors:SE Texas" and "Super Doctor". Colin P. Dinney, MD is also a published MD. He has 103 paper published. The most recent paper is: Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. Colin Dinney accepts Medicare.
Publications
- Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.
- Outcome of patients with clinically node-positive Bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Expe...
- Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
- Origins of Bladder Cancer.
- Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guerin Instillation fo...
- Multilevel-analysis identify a cis-expression quantitative trait locus associated with risk of Renal cell carcinoma.
- Clinical Outcomes in cT1 Micropapillary Bladder Cancer.
- Reply to Mattias Aine, Fredrik Liedberg, Gottfrid Sjödahl, and Mattias Höglund's Letter to the Editor re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New Ins...
- Intravesical Tumor Involvement of the Trigone Is Associated With Nodal Metastasis in Patients Undergoing Radical Cystectomy.
- Intrinsic basal and luminal subtypes of muscle-invasive Bladder cancer.
- Imputation and subset based association analysis across different Cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33.
- Micropapillary Bladder cancer: Current treatment patterns and review of the literature.
- A Genome-Wide Association Study Identifies Variants in Casein Kinase II (CSNK2A2) to be Associated with Leukocyte Telomere Length in a Punjabi Sikh Diabetic Cohort.
- Differential expression of GATA-3 in urothelial carcinoma variants.
- Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis.
- Genome-wide association study identifies multiple loci associated with Bladder cancer risk.
- Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson ...
- Fluid intake, genetic variants of UDP-glucuronosyltransferases, and Bladder cancer risk.
- Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of Bladder cancer growth and metastasis: implications for therapeutic targeting.
- Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive Bladder cancer.
- A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in loc...
- The p63 isoform ̉Np63̱ inhibits epithelial-mesenchymal transition in human Bladder cancer cells: Role of miR205.
- Plasmacytoid Urothelial Carcinomas - A Chemo-sensitive Cancer with Poor Prognosis, and Peritoneal Carcinomatosis.
- Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human Bladder cancer cells.
- Detection of Bladder cancer using proteomic profiling of urine sediments.
- Plasma microRNA profiles for Bladder cancer detection.
- Association of polymorphisms in oxidative stress genes with clinical outcomes for Bladder cancer treated with Bacillus Calmette-Guérin.
- p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in Bladder cancer cells.
- Intake of red meat and heterocyclic amines, metabolic pathway genes, and Bladder cancer risk.
- Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for Bladder cancer: results of a prospective trial.
- Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy.
- A genome-wide association study of Bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3.
- Comprehensive pathway-based interrogation of genetic variations in the nucleotide excision DNA repair pathway and risk of Bladder cancer.
- Concomitant Carcinoma in situ in Cystectomy Specimens Is Not Associated with Clinical Outcomes after Surgery.
- Prognostic risk stratification of pathological stage T3N0 Bladder cancer after radical cystectomy.
- A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for Bladder cancer.
- Prospective trial to identify optimal Bladder cancer surveillance protocol: reducing costs while maximizing sensitivity.
- Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive Bladder cancer.
- Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for Bladder cancer.
- Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy.
- Prognostic risk stratification of pathological stage T2N0 Bladder cancer after radical cystectomy.
- A multi-stage genome-wide association study of Bladder cancer identifies multiple susceptibility loci.
- A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with Bladder...
- Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive Bladder cancer.
- Upper Tract urothelial carcinoma: Impact of time to surgery.
- Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients.
- Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients.
- Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of Bladder cancer.
- Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria.
- Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in Bladder cancer.
- Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients.
- Bladder cancer: narrowing the gap between evidence and practice.
- The molecular, the bad, and the ugly: preventing Bladder cancer via mTOR inhibition.
- Cardiac history and risk of post-cystectomy cardiac complications.
- Squamous cell carcinoma of the urinary Bladder: a clinicopathologic and immunohistochemical study of 16 cases.
- Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary Bladder cancer.
- High risk populations and cystectomy outcomes.
- Dietary intake of vegetables and fruits and the modification effects of GSTM1 and NAT2 genotypes on Bladder cancer risk.
- Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial Cancer.
- Benzo(a)pyrene diol epoxide-induced chromosome 9p21 aberrations are associated with increased risk of Bladder cancer.
- Understanding the development of human Bladder cancer by using a whole-organ genomic mapping strategy.
- Evaluation of genetic variants in microRNA-related genes and risk of Bladder cancer.
- Profiling of genetic variations in inflammation pathway genes in relation to Bladder cancer predisposition.
- Clinical model of cost of Bladder cancer in the elderly.
- Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of Bladder cancer.
- Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for Bladder cancer: analysis of pooled data from MD...
- Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive Bladder cancer.
- Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the Bladder.
- Projecting individualized probabilities of developing Bladder cancer in white individuals.
- Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal Cancer.
- Organ preservation for muscle-invasive Bladder cancer by transurethral resection.
- Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the Bladder: a contemporary review of The University of Texas M D Anderson Cancer C...
- Risk assessment of Renal cell carcinoma using alkaline comet assay.
- Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and Bladder cancer risk.
- Matrix metalloproteinase polymorphisms are associated with Bladder cancer invasiveness.
- Genetic polymorphism in Bladder cancer.
- High-order interactions among genetic variants in DNA base excision repair pathway genes and smoking in Bladder cancer susceptibility.
- Matrix metalloproteinase polymorphisms and Bladder cancer risk.
- Molecular markers of urothelial Cancer and their use in the monitoring of superficial urothelial Cancer.
- Relevance of extracapsular extension of pelvic lymph node metastasis in patients with Bladder cancer treated in the contemporary era.
- Vitamins C and K3 sensitize human urothelial tumors to gemcitabine.
- Should cystectomy only be performed at high-volume hospitals by high-volume surgeons?
- Clinical model of lifetime cost of treating Bladder cancer and associated complications.
- Personal permanent hair dye use is not associated with Bladder cancer risk: evidence from a case-control study.
- Bladder cancer risk as modified by family history and smoking.
- Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in Bladder cancer: implications for therapy.
- Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy.
- Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes.
- The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human Bladder carcinoma tumors.
- Polymorphisms in inflammation genes and Bladder cancer: from initiation to recurrence, progression, and survival.
- Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial Bladder cancer.
- Integrating basic science and clinical research in Bladder cancer: update from the first Bladder Specialized Program of Research Excellence (SPORE).
- Use of the University of California Los Angeles integrated staging system to predict survival in Renal cell carcinoma: an international multicenter study.
- Evidence supporting preoperative chemotherapy for small cell carcinoma of the Bladder: a retrospective review of the M. D. Anderson cancer experience.
- Validation of an integrated staging system toward improved prognostication of patients with localized Renal cell carcinoma in an international population.
- Adenoviral p53 gene transfer in human Bladder cancer cell lines: cytotoxicity and synergy with cisplatin.
- Repeated intravesical instillations of an adenoviral vector in patients with locally advanced Bladder cancer: a phase I study of p53 gene therapy.
- Genetic instability in Bladder cancer assessed by the comet assay.
- Inhibition of growth and metastasis of orthotopic human prostate Cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel.
- Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.
- Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.
- Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with Bladder cancer risk in individuals...
Procedures Preformed
- AdRenalectomy
- Cystectomy
- Cystometry
- Cystourethroscopy and Transurethral Resection of Bladder Neck
- View All
Conditions Treated
- Balanoposthitis
- Bladder Cancer
- Bladder Infection
- Bladder Stones
- View All
Doctors Specialties
- Other
- Urology
Accepted Insurances
Awards
- Top Doctors:SE Texas
- Super Doctor
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1700984630 | |
| NPPES Provider LastName | DINNEY | |
| NPPES Provider FirstName | COLIN | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Urology | |
| Total Claim Count | 76.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1700984630 |
| Last Name Of The Provider | DINNEY |
| First Name Of The Provider | COLIN |
| View All |
Similar Doctors
|
Dr. Omar H. Durrani, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Tung Shu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Herbert L. Watkins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Herbert B. Grossman, MD |
|
|
Dr. Kelly E. Kaesler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Guilherme Godoy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mehrad Adibi, MD |
|
|
Dr. Robert Jaehne, DC
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fatima Husain, MD |
|
|
Dr. Adam B. Hollander, MD |
|
|
Dr. Philip L. Ho, MD |
|
|
Dr. Amer Wahed, MD |
|
|
Mei S. Ho, CRNA |
|
|
Dr. Eugene K. Lee, MD |